Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"
Anixa Biosciences' breast cancer vaccine was featured on Fox News' "America Reports," highlighting its potential to revolutionize breast cancer prevention by targeting the disease at its earliest stages. The vaccine trains the immune system to recognize α-lactalbumin, a protein expressed during lactation and in breast cancer cells, potentially providing preemptive protection against emerging tumors.
The ongoing Phase I clinical trial, conducted with Cleveland Clinic and funded by the U.S. Department of Defense, shows promising progress with a strong safety profile. The vaccine has been well tolerated, with protocol-defined immune responses observed in over 70% of patients. A Phase 2 study in the neoadjuvant setting is planned to begin in 2025.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, expressed optimism about the vaccine's potential impact in reducing the incidence of triple-negative breast cancer and other breast cancers.
Il vaccino contro il cancro al seno di Anixa Biosciences è stato presentato nel programma "America Reports" di Fox News, evidenziando il suo potenziale di rivoluzionare la prevenzione del cancro al seno agendo sulla malattia nelle sue fasi iniziali. Il vaccino addestra il sistema immunitario a riconoscere l'α-lattalbumina, una proteina espressa durante l'allattamento e nelle cellule del cancro al seno, fornendo potenzialmente una protezione preventiva contro i tumori emergenti.
Il trial clinico di Fase I, condotto con la Cleveland Clinic e finanziato dal Dipartimento della Difesa degli Stati Uniti, mostra progressi promettenti con un forte profilo di sicurezza. Il vaccino è stato ben tollerato, con risposte immunitarie definite dal protocollo osservate in oltre il 70% dei pazienti. È previsto l'inizio di uno studio di Fase 2 nel contesto neoadiuvante nel 2025.
Il Dr. Amit Kumar, Presidente e CEO di Anixa Biosciences, ha espresso ottimismo riguardo all'impatto potenziale del vaccino nella riduzione dell'incidenza del cancro al seno triplo negativo e di altri tipi di cancro al seno.
La vacuna contra el cáncer de mama de Anixa Biosciences fue presentada en "America Reports" de Fox News, destacando su potencial para revolucionar la prevención del cáncer de mama al dirigirse a la enfermedad en sus primeras etapas. La vacuna entrena al sistema inmunológico para reconocer la α-lactalbumina, una proteína expresada durante la lactancia y en las células de cáncer de mama, proporcionando potencialmente protección preventiva contra tumores emergentes.
El ensayo clínico de Fase I, realizado con la Cleveland Clinic y financiado por el Departamento de Defensa de EE. UU., muestra un progreso prometedor con un sólido perfil de seguridad. La vacuna ha sido bien tolerada, con respuestas inmunitarias definidas por el protocolo observadas en más del 70% de los pacientes. Se planea iniciar un estudio de Fase 2 en el contexto neoadyuvante en 2025.
El Dr. Amit Kumar, Presidente y CEO de Anixa Biosciences, expresó optimismo sobre el impacto potencial de la vacuna en la reducción de la incidencia de cáncer de mama triple negativo y otros tipos de cáncer de mama.
아닉사 바이오사이언스의 유방암 백신이 폭스 뉴스의 "아메리카 리포트"에 소개되어, 질병의 초기 단계에서 표적화함으로써 유방암 예방을 혁신할 잠재력을 강조했습니다. 이 백신은 면역 체계를 훈련시켜 수유 중에 발현되는 단백질인 α-락탈부민을 인식하게 하여, 새로운 종양에 대한 예방적 보호를 제공할 수 있습니다.
클리블랜드 클리닉과 함께 진행 중인 1상 임상 시험은 미국 국방부의 자금 지원을 받아 안전성 프로파일이 강력한 긍정적인 진전을 보여줍니다. 이 백신은 잘 견뎌졌으며, 70% 이상의 환자에서 프로토콜에 정의된 면역 반응이 관찰되었습니다. 2025년에는 보조 치료 환경에서 2상 연구가 시작될 예정입니다.
아닉사 바이오사이언스의 회장 겸 CEO인 아밋 쿠마르는 이 백신이 삼중 음성 유방암 및 기타 유방암의 발생률 감소에 미칠 잠재적 영향에 대해 낙관적인 입장을 표명했습니다.
Le vaccin contre le cancer du sein d'Anixa Biosciences a été présenté dans l'émission "America Reports" de Fox News, soulignant son potentiel à révolutionner la prévention du cancer du sein en ciblant la maladie à ses premiers stades. Le vaccin entraîne le système immunitaire à reconnaître l'α-lactalbumine, une protéine exprimée pendant l'allaitement et dans les cellules cancéreuses du sein, offrant potentiellement une protection préventive contre les tumeurs émergentes.
Le essai clinique de phase I, mené avec la Cleveland Clinic et financé par le Département de la Défense des États-Unis, montre des progrès prometteurs avec un solide profil de sécurité. Le vaccin a été bien toléré, avec des réponses immunitaires définies par le protocole observées chez plus de 70 % des patients. Une étude de phase 2 dans un contexte néoadjuvant est prévue pour débuter en 2025.
Dr. Amit Kumar, Président et PDG d'Anixa Biosciences, a exprimé son optimisme quant à l'impact potentiel du vaccin sur la réduction de l'incidence du cancer du sein triple négatif et d'autres cancers du sein.
Der Brustkrebsimpfstoff von Anixa Biosciences wurde in "America Reports" von Fox News vorgestellt und hebt sein Potenzial hervor, die Prävention von Brustkrebs zu revolutionieren, indem die Krankheit in ihren frühesten Stadien angegriffen wird. Der Impfstoff trainiert das Immunsystem, um α-Laktalbumin zu erkennen, ein Protein, das während der Stillzeit und in Brustkrebszellen exprimiert wird, und bietet möglicherweise präventiven Schutz gegen aufkommende Tumoren.
Die laufende Phase-I-Studie, die in Zusammenarbeit mit der Cleveland Clinic durchgeführt und vom US-Verteidigungsministerium finanziert wird, zeigt vielversprechende Fortschritte mit einem starken Sicherheitsprofil. Der Impfstoff wurde gut vertragen, und bei über 70 % der Patienten wurden protokollierte Immunantworten beobachtet. Eine Phase-2-Studie im neoadjuvanten Setting ist für 2025 geplant.
Dr. Amit Kumar, Vorsitzender und CEO von Anixa Biosciences, äußerte Optimismus über das potenzielle Einfluss des Impfstoffs auf die Verringerung der Inzidenz von dreifach negativem Brustkrebs und anderen Brustkrebsarten.
- Breast cancer vaccine featured on national television (Fox News)
- Phase I trial shows protocol-defined immune responses in over 70% of patients
- Vaccine demonstrates strong safety profile and is well tolerated
- Phase 2 study planned to begin in 2025
- Collaboration with Cleveland Clinic and funding from U.S. Department of Defense
- Phase I trial still ongoing with no completed efficacy data
- Vaccine remains in early development stages
Insights
The Fox News feature on Anixa's breast cancer vaccine represents increased visibility for the company's preventative approach but doesn't constitute a material clinical advancement. The underlying technology targets α-lactalbumin—a protein normally expressed only during lactation but abnormally present in many breast cancer cells—creating a highly specific target for immunotherapy that potentially minimizes off-target effects.
The reported 70% immune response rate in Phase I patients is encouraging but requires careful interpretation. Immune responses in early trials indicate biological activity but don't necessarily predict clinical efficacy in preventing cancer. The vaccine's true preventative potential won't be established until larger, longer-term studies are completed.
The planned Phase 2 trial in the neoadjuvant setting (treatment before primary therapy) represents a strategic approach to gather efficacy data more quickly than a traditional prevention trial, which would require following healthy subjects for many years. This pragmatic development path could accelerate the timeline to potential approval.
Department of Defense funding suggests external validation of the approach but also reflects the significant unmet need in triple-negative breast cancer (TNBC), which disproportionately affects younger women, including military personnel. TNBC lacks targeted therapies available for hormone-positive or HER2-positive breast cancers, making preventative approaches particularly valuable.
For investors, preventative cancer vaccines represent a different value proposition than traditional oncology drugs. The potential market is enormous—all at-risk women—but adoption would depend on robust efficacy data, favorable safety profiles, and healthcare system implementation. Media exposure could help with clinical trial recruitment, potentially accelerating development timelines.
While this news alone doesn't warrant a significant revaluation of Anixa, it does highlight the company's innovative approach in the emerging field of cancer prevention through immunotherapy, an area that could transform breast cancer management if successful in later-stage trials.
Anixa's breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells before they can develop into invasive tumors. The vaccine targets a lactation protein, α-lactalbumin, which is only expressed in the breast when a woman is lactating but not at other times in her life or in other tissues. However, when a woman develops breast cancer, including TNBC or other types of breast cancer, many of the malignant cells will express α-lactalbumin. Activating the immune system, through vaccination, to direct cytotoxic T cells to the tumor cell expressing this protein may provide preemptive immune protection against emerging breast tumors that express α-lactalbumin.
"We are pleased to have our breast cancer vaccine featured on Fox News' 'America Reports,' as this national exposure brings greater awareness to the importance of preventative cancer immunotherapy," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "We believe we have made significant strides, and we are optimistic about the impact this vaccine could have in reducing the incidence of triple-negative breast cancer as well as other breast cancers."
The Phase I clinical trial, conducted in collaboration with Cleveland Clinic and funded by a grant from the
To watch the Fox News "America Reports" feature, please visit Anixa's YouTube channel: https://www.youtube.com/watch?v=PIvp5oiK-Ac.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-breast-cancer-vaccine-was-featured-on-fox-news-america-reports-302384318.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is the mechanism of action for ANIX's breast cancer vaccine?
What results has ANIX reported from its breast cancer vaccine Phase I trial?
When will ANIX begin Phase 2 trials for its breast cancer vaccine?
Who is funding ANIX's breast cancer vaccine clinical trials?
What types of breast cancer could ANIX's vaccine potentially prevent?
